Scot Michael Elder - 22 Jan 2026 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Chief Legl & Comp Off, CorpSec
Issuer ticker: TMCI
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 21:30:08 UTC
Prior SEC filing: 13 Jan 2026
Next SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Scot Elder

Key filing fact

Scot Michael Elder filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 23 Jan 2026.

Key facts

This page summarizes Scot Michael Elder's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Jan 2026, 21:30.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001916619 Primary reporting owner

Elder Scot Michael

Relationship: Chief Legl & Comp Off, CorpSec
Address: C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA
Signature: /s/ Lisa Taylor as Attorney-in-fact for Scot Elder
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Tax liability

Transaction value: $0
Shares: -9,451
Change %: -1.7%
Price: $0.000000
Shares after: 534,286
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F1

TMCI transaction

Common Stock

Award

Transaction value: $0
Shares: +262,500
Change %: +49%
Price: $0.000000
Shares after: 796,786
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes 378,970 restricted stock units.

Footnote F2

Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date.

Footnote F3

Includes 641,470 restricted stock units.